Novo Nordisk PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Dec. 18, 2025 /PRNewswire/ -- Today, Novo Nordisk (NVO) announced the submission of a New Drug Application (NDA) to the U.S. FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain . . . This content is for paid subscribers. Please click here to …
Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone® (MIST) announced that the U.S. FDA approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Immunome Inc Immunome, Inc. (IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today the firm announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. The trial met its primary . . . This content is for paid subscribers. Please click here to …
Alnylam Pharmaceuticals Yesterday, December 11, 2025, Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggregate principal amount of the Notes for a total repurchase cost (including accrued and unpaid interest) of approximately $51.9 million . . …
Rhythm Pharmaceuticals Today, Rhythm Pharmaceuticals, Inc. (RYTM), announced positive preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). The firm also announced plans to advance setmelanotide into a Phase 3 registrational trial in PWS, pending successful completion of . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Praxis Precision Medicines Praxis Precision Medicines (PRAX) - a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, announced the completion of a Type C meeting with the U.S. Food and Drug Administration (FDA) and agreement to immediately convert the EMBRAVE3 . . . This content is for paid subscribers. Please click here to …
About Time to Remember A few days ago, Governor Ron DeSantis eliminated property taxes for property owners in Florida. The value of Structure Therapeutics’ (GPCR) increased and its stocks surged on positive phase 2b results for the obesity drug Aleniglipron. The company reported positive 36‑week topline results . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Ionis Pharmaceuticals On December 2, 2025 - Ionis Pharmaceuticals (IONS) announced that the FDA has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease (AxD), a rare, progressive and often fatal neurological condition. Over time, it can lead to loss of mobility and independence, along with difficulties walking, speaking, swallowing and breathing. There are currently no . . . This content is …
Harmony Biosciences Epilepsy News and the Treatment of Dravet Syndrome Harmony Biosciences Holdings, Inc. (HRMY), announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The ARGUS trial is currently enrolling, and …
Roche in the NEWS Basel, December 2, 2025 - Roche (RHHBY) announced that its first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver, in addition to CE IVDR certification. The . . . This content is for paid subscribers. Please …
Question & Answer About Cogen Biosciences Question From Mel Nashef Q: On November 24, 2025, you posted news about a biotech company called Cogent Biosciences (COGT). In it you wrote that the firm has positive data from Phase 3 PEAK Trial in combination of its drug . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Lilly in the NEWS INDIANAPOLIS, December 1, 2025, Eli Lilly and Company (LLY) today announced Zepbound® (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company’s digital healthcare platform. This update builds on Lilly’s ongoing efforts to lower out-of-pocket costs for people living with obesity in the United States. Last month, Lilly announced lower prices for Zepbound multi-dose pens, subject to approval by …
Cogent Biosciences Excellent NEWS Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. The Company’s primary focusses target different forms of mastocytosis and gastrointestinal stomal tumors (GIST). The firm’s positive data from Phase 3 PEAK Trial has been studied with the combination of its drug bezuclastinib with Sunitinib. Many analysts . . . This content is for paid subscribers. Please click here to …
Aspen Neuroscience Aspen Neuroscience, Inc. – a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen’s lead program, ANPD001, for moderate to advanced Parkinson’s disease. The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from …
Novo Nordisk in the NEWS On Monday, November 17, 2025, Novo Nordisk (NVO) announced that Wegovy® (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic® are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026. This introductory offer is good for the first two months of therapy and . . . This content is for paid subscribers. Please click here …
Vertex Pharmaceuticals in the NEWS On November 8, 2025, Vertex Pharmaceuticals Incorporated (VRTX) announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the . . . This content is for paid …
Cogent Biosciences On November 10, 2025, Cogent Biosciences (COGT) reported positive data from its Phase 3 PEAK trial of bezuclastinib plus sunitinib in patients with imatinib-resistant or intolerant Gastrointestinal Stromal Tumors (GIST). The combination reached a median progression free survival (mPFS) of 16.5 months compared to sunitinib monotherapy, which reached a mPFS of 9.2 months. The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Ionis Pharmaceuticals On November 8, 2025, Ionis Pharmaceuticals (IONS) announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The . . . This content is for …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
